Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours-Reference-Cited by-同舟云学术

Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours

Published:2018-11 Issue: Volume:70 Page:209-222
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Barriuso Jorge,Custodio Ana^ORCID,Afonso Ruth,Alonso Vicente,Astudillo Aurora,Capdevila Jaume,García-Carbonero Rocío^ORCID,Grande Enrique,Jimenez-Fonseca Paula,Marazuela Mónica,Rodríguez-Antona Cristina,Aller Javier

Funder

Novartis

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference130 articles.

1. Trends in the incidence, prevalence and survival outcomes in patients with neuroendocrine tumors in the United States;Dasari;JAMA Oncol,2017

2. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability and tolerance;ÓToole;Cancer,2000

3. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors;Ricci;Am J Clin Oncol,2000

4. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience;Garland;Aliment Pharmacol Ther,2003

5. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR;Toumpanakis;Aliment Pharmacol Ther,2009

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Established and novel circulating neuroendocrine tumor biomarkers for diagnostic, predictive and prognostic use;Best Practice & Research Clinical Endocrinology & Metabolism;2023-09

2. Toward tryptathionine-stapled one-bead-one-compound (OBOC) libraries: solid phase synthesis of a bioactive octretoate analog;Organic & Biomolecular Chemistry;2023

3. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies;Cancers;2022-02-28

4. Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice;Cancers;2022-02-17

5. Circulating tumour cells and tumour biomarkers in functional midgut neuroendocrine tumours;Journal of Neuroendocrinology;2022-02-07